MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

Home・Stock List・VolitionRX Ltd

VolitionRX Ltd

Open

0.18 -5.26

Buy Sell

Overview

Share price change

24h

Current

Min

0.18

Max

0.2

Key metrics
By Trading Economics
Income	936K -5.4M
Sales	221K 627K
Profit margin	-857.414
Employees	75
EBITDA	1.3M -4.2M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+1400% upside

Dividends
By Dow Jones
Next Earnings	14 May 2026

Market Stats
By TradingEconomics
Market Cap	-19M 28M
Previous open	5.44
Previous close	0.18

VolitionRX Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 Mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 Apr 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 Mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 Mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 Mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 Mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 Mar 2026, 23:14 UTC

Market Talk

Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 Mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 Mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 Mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 Mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 Mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 Mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 Mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 Mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 Mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 Mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 Mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 Mar 2026, 21:24 UTC

Market Talk

Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 Mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 Mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 Mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 Mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

VolitionRX Ltd Forecast

Price Target

By TipRanks

1400% upside

12 Months Forecast

Average 3 USD 1400%

High 3 USD

Low 3 USD

Based on 1 Wall Street analysts offering 12 month price targets forVolitionRX Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to VolitionRX Ltd - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.